ANIK (Anika Therapeutics Inc) Stock Analysis - SEC Filings

Anika Therapeutics Inc (ANIK) is a publicly traded Healthcare sector company. As of May 21, 2026, ANIK trades at $15.50 with a market cap of $198.92M and a P/E ratio of -19.92. ANIK moved +1.48% today. Year to date, ANIK is +59.87%; over the trailing twelve months it is +26.59%. Its 52-week range spans $7.87 to $25.65. Analyst consensus is buy with an average price target of $17.50. Rallies surfaces ANIK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find ANIK SEC filings?

Rallies organizes ANIK SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

ANIK Key Metrics

Key financial metrics for ANIK
MetricValue
Price$15.50
Market Cap$198.92M
P/E Ratio-19.92
EPS$-0.76
Dividend Yield0.00%
52-Week High$25.65
52-Week Low$7.87
Volume7
Avg Volume0
Revenue (TTM)$112.82M
Net Income$-10.88M
Gross Margin56.56%

Latest ANIK News

Recent ANIK Insider Trades

  • HENNEMAN JOHN B III bought 5.00K (~$73.32K) on May 1, 2026.
  • Griffin Stephen D. bought 12.20K (~$149.88K) on Apr 30, 2026.

ANIK Analyst Consensus

2 analysts cover ANIK: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $17.50.

Common questions about ANIK

Where can I find ANIK SEC filings?
Rallies organizes ANIK SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show ANIK 10-K and 10-Q filings?
Rallies organizes ANIK SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is ANIK research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ANIK. It does not provide personalized investment advice.
ANIK

ANIK